• Kindlin-3-b 2 -integrin signaling in neutrophils is involved in regulation of both neutrophil recruitment and NET release.• Disrupting the crosstalk between kindlin-3 and b 2 -integrins in neutrophils with a blocking peptide preferentially attenuates NET release.Kindlin-3 essentially supports integrin activation in blood cells. Absence of kindlin-3 in humans causes leukocyte adhesion deficiency-III characterized with severe bleeding disorder and recurrent infections. Previously, we generated kindlin-3 knock-in (K3KI) mice carrying an integrin-interaction disrupting mutation in kindlin-3 and verified the functional significance of the binding of kindlin-3 to integrin aIIbb3 in platelets. Here, using K3KI mice, we functionally evaluate the crosstalk between kindlin-3 and b 2 -integrins in neutrophils. Although the kindlin-3 mutant in K3KI neutrophils is normally expressed, its binding ability to b 2 -integrins in neutrophils is disabled. In vitro and in vivo analyses disclose that b 2 -integrin-mediated K3KI neutrophil adhesion and recruitment are significantly suppressed. Interestingly, the ability of releasing neutrophil extracellular traps (NETs) from K3KI neutrophils is also compromised. Substantially, a peptide derived from the integrin b 2 cytoplasmic tail that can inhibit the interaction between kindlin-3 and b 2 -inegrins significantly jeopardizes NET release without affecting neutrophil adhesion and recruitment under the experimental conditions. These findings suggest that crosstalk between kindlin-3 and b 2 -integrins in neutrophils is required for supporting both neutrophil recruitment and NET release, but the involved regulatory mechanisms in these two cellular events might be differential, thus providing a novel therapeutic concept to treat innate immune-related diseases. (Blood. 2015;126(3):373-377)
IntroductionNeutrophil recruitment and neutrophil extracellular trap (NET) release are hallmarks of innate immune responses. The engagement of b 2 -integrins on neutrophils with their ligands mediates firm adhesion of neutrophils to inflamed endothelium 1,2 and may also be involved in regulating NET release.3,4 Ligand-binding capability of b 2 -integrins on leukocytes is tightly regulated by a process of integrin activation, which is triggered by extracellular agonists and eventually implemented by the integrin a/b cytoplasmic tail (CT) binding proteins. 5,6 Kindlins are recently identified integrin b CT binding proteins, and kindlin-3, one of the 3 kindlin family members, is mainly expressed in hematopoietic cells.7-9 Kindlin-3 mutants in humans are responsible for type III leukocyte adhesion deficiency (LAD-III) with severe bleeding tendency and recurrent infections due to the dysfunction of integrins in both leukocytes and platelets. 10,11 Since the first case was described in 1997, a list of LAD-III patients from more than 20 families have been reported so far. The identified kindlin-3 mutations in these patients vary but all result in undetectable expression of kindlin-3 protein in blood cells...